selected scholarly activity
-
academic article
- Hypophosphatasia: Canadian update on diagnosis and management. Osteoporosis International. 30:1713-1722. 2019
- Correction to: Hypophosphatasia: Canadian update on diagnosis and management. Osteoporosis International. 30:1541-1541. 2019
- Score Distributions of the Balance Outcome Measure for Elder Rehabilitation (BOOMER) in Community-Dwelling Older Adults With Vertebral Fracture. Journal of Geriatric Physical Therapy. 42:E87-E93. 2019
- Tools for Enhancement and Quality Improvement of Peer Assessment and Clinical Care in Endocrinology and Metabolism. Journal of Clinical Densitometry. 22:125-149. 2019
- Medical Hypoparathyroidism. Endocrinology and Metabolism Clinics of North America. 47:797-808. 2018
- FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab. Journal of Bone and Mineral Research. 33:1219-1226. 2018
- Hyperparathyroidism. The Lancet. 391:168-178. 2018
- A weekly 35,000 IU vitamin D supplementation improves bone turnover markers in vitamin D deficient Saudi adolescent females. Archives of Osteoporosis. 12:85. 2017
- A weekly 35,000 IU vitamin D supplementation improves bone turnover markers in vitamin D-deficient Saudi adolescent females: response to comments by Ribaldone et al.. Archives of Osteoporosis. 12:101. 2017
- Primary hyperparathyroidism: diagnosis and management in 2017. Polskie Archiwum Medycyny Wewnetrznej. 127:438-441. 2017
- Atypical femoral fracture. CMAJ. 189:E542-E542. 2017
- Drug-Related Adverse Events of Osteoporosis Therapy. Endocrinology and Metabolism Clinics of North America. 46:181-192. 2017
- Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. Journal of Clinical Densitometry. 20:8-24. 2017
- Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporosis International. 28:1-19. 2017
- Ostéoporose pendant la ménopause. Journal of Obstetrics and Gynaecology Canada. 38:S465-S483. 2016
- Primary hyperparathyroidism. Nature Reviews Disease Primers. 2:16033. 2016
- Vitamin D deficiency and biochemical variations among urban Saudi adolescent girls according to season. Saudi Medical Journal. 37:1002-1008. 2016
- Atypical Femoral Fracture Alert Program. Canadian Association of Radiologists Journal. 67:304-305. 2016
- Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporosis International. 27:853-859. 2016
- Bilateral atypical femoral fractures: how much symmetry is there on imaging?. Skeletal Radiology. 44:1579-1584. 2015
- Persistence with denosumab therapy among osteoporotic women in the Canadian patient-support program. Current Medical Research and Opinion. 31:1391-1401. 2015
- Response to Comments on “Diagnosis and Management of Osteoporosis of the Jaw: A Systematic Review and International Consensus”. Journal of Bone and Mineral Research. 30:1116-1117. 2015
- Atypical Femoral Fractures: A Teaching Perspective. Canadian Association of Radiologists Journal. 66:102-107. 2015
- Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery. European Journal of Endocrinology. 172:527-535. 2015
- Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus. Journal of Bone and Mineral Research. 30:3-23. 2015
- OSTEONECROSIS OF THE JAW: AN UPDATE FOR DENTISTS.. Journal of the Canadian Dental Association. 81:f19. 2015
- Medical Management of Primary Hyperparathyroidism: Proceedings of the Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism. 99:3607-3618. 2014
- Osteoporosis in Menopause. Journal of Obstetrics and Gynaecology Canada. 36:839-840. 2014
- The bisphosphonates in the treatment of osteoporosis Expected Benefits, potential harms and therapeutic time off. Canadian Family Physician. 60:E197-E207. 2014
- Improving Management of Osteoporosis through Simple Changes in Reporting Fragility Fractures. Canadian Association of Radiologists Journal. 64:278-280. 2013
- Approach to diagnosing celiac disease in patients with low bone mineral density or fragility fractures: multidisciplinary task force report.. Canadian Family Physician. 59:1055-e448. 2013
- Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis. Current Medical Research and Opinion. 29:205-216. 2013
- Medical Management of Primary Hyperparathyroidism. Journal of Clinical Densitometry. 16:60-63. 2013
- Supplement on Primary Hyperparathyroidism. Journal of Clinical Densitometry. 16:3-3. 2013
- Diagnosis and management of primary hyperparathyroidism. British Medical Journal BMJ (Clinical research ed.). 344:e1013-e1013. 2012
- Evaluation and Management of Skeletal Health in Celiac Disease: Position Statement. Canadian Journal of Gastroenterology. 26:819-829. 2012
- Primary hyperparathyroidism. CMAJ. 183:E685-E689. 2011
- Bisphosphonate-associated Osteonecrosis of the Jaw in Ontario: A Survey of Oral and Maxillofacial Surgeons. Journal of Rheumatology. 38:1396-1402. 2011
- Official Positions for FRAX® Bone Mineral Density and FRAX® Simplification. Journal of Clinical Densitometry. 14:226-236. 2011
- Primary hyperparathyroidism: Update on presentation, diagnosis, and management in primary care.. Canadian Family Physician. 57:184-189. 2011
- Primary Hyperparathyroidism: An Overview. International Journal of Endocrinology. 2011:1-8. 2011
- Asymptomatic Primary Hyperparathyroidism—Commentary on Current Management. Journal of Clinical Densitometry. 13:321-323. 2010
- Osteonecrosis of the jaw and bisphosphonates. British Medical Journal BMJ (Clinical research ed.). 340:c246-c246. 2010
- Alendronate Therapy in Men with Primary Hyperparathyroidism. Endocrine Practice. 15:705-713. 2009
- Asymptomatic Primary Hyperparathyroidism: A Commentary on the Revised Guidelines. Endocrine Practice. 15:494-498. 2009
- Risk factors for low BMD in healthy men age 50 years or older: a systematic review. Osteoporosis International. 20:507-518. 2009
- Bisphosphonate Associated Osteonecrosis of the Jaw. Journal of Rheumatology. 36:478-490. 2009
- Dr. Khan, Dr. Hanley, and Dr. Peters reply. Journal of Rheumatology. 36:453.1-453. 2009
- Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop. Journal of Clinical Endocrinology and Metabolism. 94:335-339. 2009
- The Diagnosis and Management of Asymptomatic Primary Hyperparathyroidism Revisited. Journal of Clinical Endocrinology and Metabolism. 94:333-334. 2009
- Bisphosphonate-associated osteonecrosis of the jaw.. Canadian Family Physician. 54:1019-1021. 2008
- Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.. Journal of Rheumatology. 35:1391-1397. 2008
- Osteonecrosis of the jaw: new developments in an old disease.. Journal of Rheumatology. 35:547-549. 2008
- Cancer Treatment Related Bone Loss. Current Oncology. 15:30-40. 2008
- Dual-Energy X-Ray Absorptiometry Technical Issues: The 2007 ISCD Official Positions. Journal of Clinical Densitometry. 11:109-122. 2008
- Screening men for osteoporosis. CMAJ. 177:1069-1069. 2007
- Recommendations for Bone Mineral Density Reporting in Canada: A Shift to Absolute Fracture Risk Assessment. Journal of Clinical Densitometry. 10:120-123. 2007
- Standards and Guidelines for Technologists Performing Central Dual-Energy X-Ray Absorptiometry. Journal of Clinical Densitometry. 10:189-195. 2007
- Recognizing and reporting vertebral fractures: reducing the risk of future osteoporotic fractures.. Canadian Association of Radiologists Journal. 58:27-36. 2007
- Management of osteoporosis in men: an update and case example. CMAJ. 176:345-348. 2007
- Bone Mineral Density Assessment in Premenopausal Women. Women's Health Women's health (London, England). 2:639-645. 2006
- Premenopausal women and low bone density.. Canadian Family Physician. 52:743-747. 2006
- Anabolic Agents: A New Chapter in the Management of Osteoporosis. Journal of Obstetrics and Gynaecology Canada. 28:136-141. 2006
- Standards for Performing DXA in Individuals With Secondary Causes of Osteoporosis. Journal of Clinical Densitometry. 9:47-57. 2006
- Prevalence of Vitamin D Inadequacy among Postmenopausal North American Women Receiving Osteoporosis Therapy. Journal of Clinical Endocrinology and Metabolism. 90:3215-3224. 2005
- Recommendations for bone mineral density reporting in Canada.. Canadian Association of Radiologists Journal. 56:178-188. 2005
- Management of Low Bone Mineral Density in Premenopausal Women. Journal of Obstetrics and Gynaecology Canada. 27:345-349. 2005
- Alendronate in Primary Hyperparathyroidism: A Double-Blind, Randomized, Placebo-Controlled Trial. Journal of Clinical Endocrinology and Metabolism. 89:3319-3325. 2004
- Standards and Guidelines for Performing Central Dual-Energy X-Ray Absorptiometry in Premenopausal Women, Men, and ChildrenA Report From the Canadian Panel† of the International Society of Clinical Densitometry. Journal of Clinical Densitometry. 7:51-63. 2004
- Persistent Primary Hyperparathyroidism Caused by Adenomas Identified in Pharyngeal or Adjacent Structures. World Journal of Surgery. 27:675-679. 2003
- Advances in osteoporosis therapy. 2003 update of practical guidelines.. Canadian Family Physician. 49:441-447. 2003
- Standards and Guidelines for Performing Central Dual X-Ray Densitometry from the Canadian Panel of International Society for Clinical Densitometry. Journal of Clinical Densitometry. 5:435-445. 2002
- The 2002 Canadian bone densitometry recommendations: take-home messages.. CMAJ. 167:1141-1145. 2002
- Standards and Guidelines for Performing Central Dual X-Ray Densitometry from the Canadian Panel of International Society for Clinical Densitometry. Journal of Clinical Densitometry. 5:247-257. 2002
- Bone Densitometry: Applications and Limitations. Journal of Obstetrics and Gynaecology Canada. 24:476-484. 2002
- SKELETAL EFFECTS OF PRIMARY HYPERPARATHYROIDISM. Endocrine Practice. 6:385-388. 2000
- Primary hyperparathyroidism: pathophysiology and impact on bone.. CMAJ. 163:184-187. 2000
- PRIMARY HYPERPARATHYROIDISM: DIAGNOSIS AND MANAGEMENT. Endocrine Practice. 3:22-26. 1997
- [Primary hyperparathyroidism].. Tidsskrift for den Norske Laegeforening. 102:1435-1437. 1982
-
conference paper
- Build better bones with exercise: feasibility of a multicenter randomized controlled trial of 12 months of home exercise in women with a vertebral fracture.. Journal of Bone and Mineral Research. S258-S259. 2017
- The Placebo-Controlled Fracture Study in Postmenopausal Women with Osteoporosis: The Foundation Effect of Rebuilding Bone with One Year of Romosozumab Leads to Continued Lower Fracture Risk after Transition to Denosumab. Arthritis and Rheumatology. 2017
- OSTEOPOROSIS THERAPY: LONG-TERM BENEFITS AND RISKS. Osteoporosis International. S425-S425. 2015
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Alendronate on Bone Mineral Density and Bone Remodelling in Perimenopausal Women With Low Bone Mineral Density. Journal of Obstetrics and Gynaecology Canada. 976-982. 2014
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Alendronate (ALN) on Bone Mineral Density (BMD) and Bone Turnover in Perimenopausal Women with Low BMD. Endocrine Reviews Recent Progress in Hormone Research. 2014
- Cinacalcet Normalizes Serum Calcium in a Randomized, Placebo-Controlled Clinical Study in Patients with Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy. Endocrine Reviews Recent Progress in Hormone Research. 2014
- 12-MONTH PERSISTENCE WITH DENOSUMAB THERAPY AMONG OSTEOPOROTIC WOMEN IN THE CANADIAN PATIENT-SUPPORT PROGRAM. Osteoporosis International. S221-S221. 2014
- OSTEONECROSIS OF THE JAW: REPORT FROM THE INTERNATIONAL ONJ TASK FORCE. Osteoporosis International. S148-S149. 2014
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF ALENDRONATE (ALN) ON BONE MINERAL DENSITY (BMD) AND BONE TURNOVER IN PERIMENOPAUSAL WOMEN WITH LOW BMD. Osteoporosis International. S55-S56. 2014
- DEVELOPMENT OF RECOMMENDATIONS FOR RADIOLOGISTS REGARDING THE EVALUATION AND MANAGEMENT OF OSTEOPOROSIS WHEN REPORTING MAJOR OSTEOPOROTIC FRACTURES IN THOSE OVER AGE 50. Osteoporosis International. S47-S48. 2014
- International Consensus on Diagnosis and Management of Osteonecrosis of the Jaw. Journal of Bone and Mineral Research. 2013
- HYPERPARATHYROIDISM. Osteoporosis International. 659-660. 2012
- Medical Management of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop. Journal of Clinical Endocrinology and Metabolism. 373-381. 2009
- Diagnosis and evaluation of secondary osteoporosis in young adults. Calcified Tissue International. S18-S18. 2008
- Alendronate in primary hyperparathyroidism: Efficacy in men and premenopausal women.. Journal of Bone and Mineral Research. S438-S438. 2006
- Alendronate in primary hyperparathyroidism: Efficacy in men and premenopausal women. Osteoporosis International. S314-S314. 2006
- Vitamin D insufficiency is highly prevalent among North American women treated for osteoporosis.. Journal of Bone and Mineral Research. S342-S343. 2004
- Bone Densitometry in Premenopausal Women. Journal of Clinical Densitometry. 85-92. 2004
- A double blind randomized placebo controlled trial of alendronate in primary hyperparathyroidism.. Journal of Bone and Mineral Research. S98-S98. 2003
- A double blind randomized placebo controlled trial of alendronate in primary hyperparathyroidism.. Journal of Bone and Mineral Research. S165-S165. 2002
- A double blind randomized placebo controlled trial of alendronate in primary hyperparathyroidism.. Journal of Bone and Mineral Research. S226-S226. 2001